Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients

Fig. 3

Kaplan-Meier PFS plots of CTC HER2-positive and -negative patients in subgroups of time interval (between tissue and CTC HER2 testing) > 1 year (a) and < 1 year (b). PFS was calculated from the time of the baseline blood draw. The coordinates of the dashed lines indicate median survival time

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us